reports
Royalty Pharma Appoints Dr. Ted W. Love As Lead Independent Director
Royalty Pharma Appoints Dr. Ted W. Love As Lead Independent Director NEW YORK, Sept. 29, 2025 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that the independent directors of the Board have unanimously appointed Dr. Ted W. Love, an independent director since 2020, as Lead Independent Director. Dr. Love will continue to Chair the Nominating and Corporate Governance Committee. “I am delighted to welcome Ted to the key role of Lead Independent Director,” said Pablo Legorreta, Chief Executive Officer of Royalty Pharma and Chairman of the Board. “Ted has extensive resea...
Royalty Pharma to Present at Bernstein’s 2nd Annual Healthcare Forum
Royalty Pharma to Present at Bernstein’s 2nd Annual Healthcare Forum NEW YORK, Sept. 19, 2025 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it will participate in a fireside chat at Bernstein’s 2nd Annual Healthcare Forum on Tuesday, September 23, 2025 at 2:50 p.m. ET. The webcast will be accessible from Royalty Pharma’s “Events” page at . The webcast will also be archived for a minimum of thirty days. About Royalty Pharma Founded in 1996, Royalty Pharma is the largest buyer of biopharmaceutical royalties and a leading funder of innovation across the...
Winmark Corp: 1 director
A director at Winmark Corp sold 852 shares at 505.017USD and the significance rating of the trade was 71/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly show...
Royalty Pharma Investor Day Highlights Strong Growth Outlook and Compa...
Royalty Pharma Investor Day Highlights Strong Growth Outlook and Company’s Plans to Drive Value Creation On track to deliver Portfolio Receipts of $4.7 billion or more by 2030, significantly ahead of consensusGoal to achieve at least mid-teens average annual total shareholder return over next 5 years with significant upside potential from recognition for Royalty Pharma’s platform valueInvestments since 2020 on track to deliver mid-teens unlevered IRR, ahead of targetAchieved 15% Return on Invested Capital (ROIC) and 21% Return on Invested Equity (ROIE) since 2019Royalty market continues to ...
Potbelly Corporation to be Acquired by RaceTrac in Approximately $566 ...
Potbelly Corporation to be Acquired by RaceTrac in Approximately $566 Million Transaction High-Growth Neighborhood Sandwich Shop Concept to be Acquired by Leading Convenience Retailer for $17.12 per share CHICAGO, Sept. 10, 2025 (GLOBE NEWSWIRE) -- Potbelly Corporation (NASDAQ: PBPB) (“Potbelly” or the “Company”), the iconic neighborhood sandwich shop concept, announced today that Potbelly and RaceTrac, Inc. (“RaceTrac”), one of the largest privately held companies in the United States and a leading convenience retailer, have entered into a definitive merger agreement pursuant to which ...
Royalty Pharma Announces Release of Deloitte’s Report on the Biopharma...
Royalty Pharma Announces Release of Deloitte’s Report on the Biopharma Royalty Market First of its kind report offers insight from over 110 biopharma executives into the benefits of royalties, current market dynamics and outlook for royalty market expansionRoyalties have become integral to biopharma’s diversified capital landscape driven by attractive cost of capital, flexibility and positive investor perception NEW YORK, Sept. 10, 2025 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced the release of a biopharma royalty market study conducted by Deloitte. The report, ...
Royalty Pharma to Present at the Morgan Stanley 23rd Annual Global Hea...
Royalty Pharma to Present at the Morgan Stanley 23rd Annual Global Healthcare Conference NEW YORK, Sept. 04, 2025 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it will participate in a fireside chat at the Morgan Stanley 23rd Annual Global Healthcare Conference on Tuesday, September 9, 2025 at 3:20 p.m. ET. The webcast will be accessible from Royalty Pharma’s “Events” page at . The webcast will also be archived for a minimum of thirty days. About Royalty Pharma Founded in 1996, Royalty Pharma is the largest buyer of biopharmaceutical royalties and a ...
Royalty Pharma Announces Pricing of $2.0 Billion of Senior Unsecured N...
Royalty Pharma Announces Pricing of $2.0 Billion of Senior Unsecured Notes NEW YORK, Sept. 02, 2025 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) announced today that it has priced an offering of $2.0 billion of senior unsecured notes, comprised of the following (collectively, the “Notes”): $600 million of 4.450% Notes due 2031 (the “2031 Notes”);$900 million of 5.200% Notes due 2035 (the “2035 Notes”); and$500 million of 5.950% Notes due 2055 (the “2055 Notes”). The Notes will be guaranteed on a senior unsecured basis by Royalty Pharma Holdings Ltd and Royalty Pharma Manager, L...
Moody's Ratings assigns Baa2 rating to Royalty Pharma's new senior uns...
Moody's Ratings (Moody's) assigned Baa2 ratings to the new backed senior unsecured notes of Royalty Pharma plc ("Royalty Pharma"). There are no changes to Royalty Pharma's existing ratings including the Baa2 senior unsecured ratings. The outlook remains unchanged at stable. The proceeds from the o...
Royalty Pharma and Zenas BioPharma Enter Into Obexelimab Funding Agree...
Royalty Pharma and Zenas BioPharma Enter Into Obexelimab Funding Agreement for Up to $300 Million Initial $75 million to fund the potential U.S. commercial launch of obexelimab for the treatment of IgG4-Related DiseaseAdditional $150 million associated with the upcoming results of the obexelimab Phase 3 INDIGO trial and FDA approval for the treatment of IgG4-Related Disease NEW YORK and WALTHAM, Mass., Sept. 02, 2025 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) and Zenas BioPharma, Inc. (Nasdaq: ZBIO) today announced that Royalty Pharma will provide up to $300 million in fundi...
- Dave Nicoski
- Ross LaDuke
Vermilion Compass: Weekly Equity Strategy
DJI and Russell 2000 Breaking Out; Staying Bullish We remain near-term bullish since our 4/22/25 Compass, and our intermediate-term outlook remains bullish as well (as of our 5/14/25 Compass). The S&P 500 (SPX) is trading within a well-defined 3+ month uptrend that began in late-May. We will maintain our bullish outlook as long as market dynamics remain healthy and the SPX is above 6028-6059. Short-term supports on SPX include 6400-6410, the 3-month uptrend (currently at ~6380), 6200, 6100-6150,...
WSM WILLIAMS-SONOMA INC.
TPH TRI POINTE HOMES INC.
NVR NVR INC.
MTH MERITAGE HOMES CORPORATION
LEN LENNAR CORPORATION CLASS A
KBH KB HOME
HVT HAVERTY FURNITURE COS. INC.
DHI D.R. HORTON INC.
OII OCEANEERING INTERNATIONAL INC.
TMHC TAYLOR MORRISON HOME CORPORATION
MHO M/I HOMES INC.
TEC TECHNIPFMC PLC
CVCO CAVCO INDUSTRIES INC.
TDW TIDEWATER INC
SOCA SUBSEA 7 S.A. ADS
ARHS ARHAUS INC
BRISTOW GROUP INC
Royalty Pharma to Acquire Royalty Interest in Amgen’s Imdelltra for up...
Royalty Pharma to Acquire Royalty Interest in Amgen’s Imdelltra for up to $950 Million Imdelltra is a first-in-class immunotherapy for the treatment of extensive-stage small cell lung cancer (ES-SCLC) marketed by AmgenRoyalty Pharma to pay $885 million upfront; BeOne Medicines to retain a $65 million option to sell additional portion of its royalty NEW YORK, Aug. 25, 2025 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it has acquired a royalty interest in Amgen’s Imdelltra, a first-in-class DLL3 targeting bispecific T-cell engager (BiTE), from BeOne Medicines ...
Henry Fernandez Steps Down from Royalty Pharma's Board of Directors
Henry Fernandez Steps Down from Royalty Pharma's Board of Directors NEW YORK, Aug. 13, 2025 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that Henry Fernandez, its Lead Independent Director, has stepped down from its Board of Directors, effective August 13, 2025. Mr. Fernandez joined the Royalty Pharma Board of Directors in July 2020 and was unanimously appointed as Lead Independent Director in March 2021. “We are tremendously grateful for Henry's contributions to Royalty Pharma over the past five years,” said Pablo Legorreta, founder and Chief Executive Officer o...
Potbelly Corporation Reports Results for Second Fiscal Quarter 2025
Potbelly Corporation Reports Results for Second Fiscal Quarter 2025 Second quarter system-wide sales growth of 6.7% including 3.2% company-operated same-store sales growth and positive traffic growth Eight shop openings and 54 additional franchise shop commitments in the second quarter Raises full-year guidance and introduces 3Q'25 guidance including positive same-store sales of 3.25%-4.25% CHICAGO, Aug. 06, 2025 (GLOBE NEWSWIRE) -- Potbelly Corporation (NASDAQ: PBPB), (“Potbelly” or the “Company”) the iconic neighborhood sandwich shop concept, today reported financial results for its ...
Tidewater Inc: 1 director
A director at Tidewater Inc sold 10,000 shares at 57.564USD and the significance rating of the trade was 63/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly s...
Royalty Pharma Reports Second Quarter 2025 Results
Royalty Pharma Reports Second Quarter 2025 Results Portfolio Receipts growth of 20% to $727 million; Royalty Receipts growth of 11%Net cash provided by operating activities of $364 millionRaised full year 2025 guidance: Portfolio Receipts expected to be $3,050 to $3,150 million NEW YORK, Aug. 06, 2025 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today reported financial results for the second quarter of 2025 and raised full year 2025 guidance for Portfolio Receipts. “We delivered excellent second quarter 2025 results, as the strength of our diversified portfolio drove 20% grow...
Texas Capital Bancshares, Inc. Announces Quarterly Dividend for Prefer...
Texas Capital Bancshares, Inc. Announces Quarterly Dividend for Preferred Stock DALLAS, July 21, 2025 (GLOBE NEWSWIRE) -- Texas Capital Bancshares, Inc. (NASDAQ: TCBI), the parent company of Texas Capital Bank, and its board of directors declared a cash dividend of $14.375 per share of the 5.75% Fixed Rate Non-Cumulative Perpetual Preferred Stock, Series B (the “Series B Preferred Stock”), equivalent to $0.359375 per depositary share, each representing a 1/40th interest in a share of the Series B Preferred Stock. The depositary shares are traded on the NASDAQ under the symbol “TCBIO.” The...
Potbelly Corporation Announces Conference Call to Discuss Second Quart...
Potbelly Corporation Announces Conference Call to Discuss Second Quarter 2025 Results on August 6, 2025 CHICAGO, July 21, 2025 (GLOBE NEWSWIRE) -- Potbelly Corporation (NASDAQ: (“Potbelly” or the “Company”), the iconic neighborhood sandwich shop concept, today announced the date for the release of its second quarter 2025 financial results. Second Quarter 2025 ResultsPotbelly will report its financial results for the fiscal second quarter 2025 on Wednesday, August 6, 2025, after market close. The Company has scheduled a conference call for investors at 5:00 p.m. Eastern Time on the same ...
Royalty Pharma Declares Third Quarter 2025 Dividend
Royalty Pharma Declares Third Quarter 2025 Dividend NEW YORK, July 18, 2025 (GLOBE NEWSWIRE) -- The board of directors of Royalty Pharma plc (Nasdaq: RPRX) has approved the payment of a dividend for the third quarter of 2025 of $0.22 per Class A ordinary share. The dividend will be paid on September 10, 2025, to shareholders of record at the close of business on August 15, 2025. About Royalty Pharma Founded in 1996, Royalty Pharma is the largest buyer of biopharmaceutical royalties and a leading funder of innovation across the biopharmaceutical industry, collaborating with innovators ...
Royalty Pharma Appoints Carole Ho and Elizabeth Weatherman to the Comp...
Royalty Pharma Appoints Carole Ho and Elizabeth Weatherman to the Company’s Board of Directors Strengthens Board of Directors with appointment of two new independent members, increasing independent representation to greater than 90%Underscores Royalty Pharma’s commitment to enhanced corporate governance following acquisition of its external manager NEW YORK, July 17, 2025 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced the appointment of Carole Ho and Elizabeth (Bess) Weatherman to its Board of Directors, effective immediately. Carole Ho is Chief Medical Officer and...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.